Eli Lilly | LLY - Cost Of Sales


Eli Lilly reported $3.58B in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Abbott USD 5.3B 380M Mar/2026
ALKERMES USD 73.25M 27.04M Mar/2026
Amgen USD 1.6B 187M Mar/2026
AstraZeneca USD -204M 3.48B Mar/2026
Baxter International USD 1.81B 587M Mar/2026
Biogen USD 797.5M 302M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Coherus Biosciences USD 4.04M 324K Dec/2025
Drreddys Laboratories INR 40.46B 3.64B Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Glaxosmithkline GBP 3.47B 461.37M Dec/2025
J&J USD 8.07B 103M Mar/2026
Medtronic USD 3.8B 195M Mar/2026
Merck USD 2.94B 380M Mar/2026
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Novartis USD 3.54B 7M Dec/2025
Novo Nordisk DKK 13.6B 1.55B Mar/2026
Perrigo USD 643.7M 103.7M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Phibro Animal Health USD 240.42M 2.58M Dec/2025
Prestige Brands USD 140.76M 9.53M Mar/2026
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 3.67B 621M Mar/2026
Sanofi EUR 3.76B 344M Dec/2025
United Therapeutics USD 133.4M 341.3M Mar/2026
Zoetis USD 672M 71M Mar/2026